Markets:

Overview

News

Currencies

International

Treasuries

Catalyst Pharmaceuticals, Inc. - Common Stock (NQ:CPRX)

23.41 -0.02 (-0.09%)

Streaming Delayed Price Updated: 1:00 PM EST, Nov 28, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Catalyst Pharmaceuticals, Inc. - Common Stock

< Previous 1 2

...

7 8 9 10 11 12 13 14 Next >

Dow, Nasdaq Boasting Triple-Digit Midday Lead ↗

January 23, 2023

Investors seem intent on leaving last week's losses behind, as earnings season heats up.

Via Talk Markets

12 Health Care Stocks Moving In Monday's Intraday Session ↗

January 23, 2023

Via Benzinga

Dow Jumps Over 300 Points; Crude Oil Up 1% ↗

January 23, 2023

U.S. stocks traded higher midway through trading, with the Dow Jones gaining more than 30 points on Monday. The Dow traded up 0.94% to 33,687.69 while the NASDAQ rose 1.93% to 11,355.16. The S&P 500...

Via Benzinga

Catalyst Pharmaceuticals, Xylem And Other Big Stocks Moving Lower On Monday ↗

January 23, 2023

U.S. stocks traded higher, with the Dow Jones gaining over 300 points on Monday. Here are some big stocks recording losses in today’s session.

Via Benzinga

$1000 Invested In This Stock 10 Years Ago Would Be Worth $27,000 Today ↗

January 23, 2023

Via Benzinga

Analyst Expectations for Catalyst Pharmaceuticals's Future ↗

January 19, 2023

Via Benzinga

HC Wainwright & Co. Maintains Buy Rating for Catalyst Pharmaceuticals: Here's What You Need To Know ↗

December 21, 2022

Via Benzinga

Catalyst Pharmaceuticals Earnings Perspective: Return On Capital Employed ↗

December 15, 2022

Via Benzinga

Catalyst Pharma Shares Take A Hit As Teva Files For Generic Version Of Its Lead Product ↗

January 23, 2023

Via Benzinga

US Stocks Mostly Higher; Synchrony Financial Earnings Top Views ↗

January 23, 2023

U.S. stocks traded mostly higher this morning, with the Nasdaq Composite gaining around 90 points on Monday.

Via Benzinga

No. 1 IBD 50 Stock Catalyst Tanks As Teva Looks To Knock Off Its Only Product ↗

January 23, 2023

Shares have sat atop the IBD 50 for weeks, have perfect ratings and recently hit a profit-taking zone.

Via Investor's Business Daily

Why Catalyst Pharmaceuticals Shares Are Moving ↗

January 23, 2023

Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) shares are trading lower by 13.46% to $18.00 Monday morning after Teva Pharmaceuticals stated it plans to sell a generic version of Catalyst's FIRDAPSE in...

Via Benzinga

Catalyst Pharmaceuticals Notified of Abbreviated New Drug Application Filing for FIRDAPSE®

January 23, 2023

From Catalyst Pharmaceuticals, Inc.

Via GlobeNewswire

2 Biotechs Making Waves With A Single Product in their Pipeline

January 11, 2023

Catalyst Pharmaceuticals and Harmony Bioscience each have a single product in their respective pipelines, and both show incredible promise.

Via MarketBeat

IDEXX Laboratories Stock Clears Technical Benchmark, Hitting 80-Plus RS Rating ↗

January 09, 2023

IDEXX Laboratories sees its Relative Strength Rating reach the 80-plus level.

Via Investor's Business Daily

Top Picks For 2023: Catalyst Pharmaceuticals - Sunday, Jan. 8 ↗

January 08, 2023

For a growth-oriented choice for the new year, I'm going with under-the-radar company, Catalyst Pharmaceuticals. Let's take a look at the company's fundamentals, technicals, and institutional support...

Via Talk Markets

Top Picks For 2023: Catalyst Pharmaceuticals ↗

January 02, 2023

Catalyst Pharmaceuticals is a small-cap biopharma company focused on in-licensing, developing, and commercializing novel medicines to treat rare diseases. Let's take a closer look to see why it's a top...

Via Talk Markets

Catalyst Pharma Acquires US Rights To Eisai's Epilepsy Drug ↗

December 20, 2022

Via Benzinga

Catalyst Pharmaceuticals to Acquire U.S. Commercial Rights to FYCOMPA® (Perampanel) CIII From Eisai Co., Ltd

December 19, 2022

From Catalyst Pharmaceuticals, Inc.

Via GlobeNewswire

This Growth Stock's Jaw-Dropping Run-Up Is Smashing Tesla's ↗

December 16, 2022

It's practically printing cash, and even more is on the way.

Via The Motley Fool

Moderna Stock Shows Surprising Strength; Key Rating Upgraded ↗

December 14, 2022

See if Moderna stock forms a new pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day average.

Via Investor's Business Daily

Xenon Pharmaceuticals Stock Scores Rising Relative Strength Upgrade ↗

November 29, 2022

Xenon Pharmaceuticals stock had its Relative Strength (RS) Rating upgraded to 92 Tuesday, up from 89 a day earlier.

Via Investor's Business Daily

Best Buy, Abercrombie & Fitch, Burlington Stores And Some Other Big Stocks Moving Higher On Tuesday ↗

November 22, 2022

U.S. stocks traded higher, with the Dow Jones gaining around 250 points on Tuesday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Stock Market Rally Roars Higher On Cooling Inflation; Bitcoin, Meta, Tesla In Focus: Weekly Review ↗

November 11, 2022

Bitcoin hit a two-year low while Meta and Tesla were in focus.

Via Investor's Business Daily

Is Mid-Cap Neurocrine Biosciences A Buy After Blowout Q3 Report?

November 11, 2022

Neurocrine Biosciences trended higher with the broad market Thursday, coming within a penny of Tuesday’s high of $125.99. It is forming a bullish channel.

Via MarketBeat

Catalyst Pharma, The No. 1 IBD 50 Stock, Just Trounced Third-Quarter Expectations ↗

November 09, 2022

The company sells one drug, a treat for a rare muscle contraction condition.

Via Investor's Business Daily

Catalyst Pharmaceuticals Reports Record Third Quarter 2022 Financial Results and Provides a Corporate Update

November 09, 2022

From Catalyst Pharmaceuticals, Inc.

Via GlobeNewswire

Catalyst Pharmaceuticals Named BioFlorida 2022 Company of the Year

November 07, 2022

From Catalyst Pharmaceuticals, Inc.

Via GlobeNewswire

Can Mid-Cap Lantheus Continue its 2022 Outperformance?

October 28, 2022

Mid-cap Lantheus Holdings has been on a revenue growth spurt boosted by a new product called Pylarify, which helps detect prostate cancer in an imaging test.

Via MarketBeat

Topics ETFs Initial Public Offering

Catalyst Pharmaceuticals to Report Third Quarter 2022 Financial Results on November 9, 2022

October 25, 2022

Conference Call and Webcast to be held on November 10, 2022, at 8:30 AM ET

From Catalyst Pharmaceuticals, Inc.

Via GlobeNewswire

< Previous 1 2

...

7 8 9 10 11 12 13 14 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.